Abstract
Background: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK-PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. Aim: To validate the UK-PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK-PBC and GLOBE scoring systems. Methods: We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti-gp210+ and 143 anti-gp210− patients. Results: The 5-year adverse outcome-free survivals of anti-gp210+ vs. anti-gp210− patients were 70% and 85%, respectively (P = 0.005). Cirrhosis (P = 0.001), albumin level ≤40 g/L (P = 0.011) and platelet count ≤153 × 109 (P < 0.001) had a superimposition effect on anti-gp210 antibody as a risk factor. Furthermore, long-term prognoses were evaluated using the UK-PBC and GLOBE scores. For UK-PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti-gp210+ patients (n = 110) and 0.888 for anti-gp210− patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti-gp210+ patients (n = 110) and 0.848 for anti-gp210− patients (n = 113). UK-PBC score >0.0578 (P < 0.001, HR: 32.736, 95% CI: 11.368–94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95% CI: 7.968–44.180) were associated with poorer outcomes in the whole cohort. Conclusions: The UK-PBC and GLOBE scoring systems were good 5-year prognostic predictors in Chinese patients with PBC, especially in anti-gp210+ patients. As a biomarker, anti-gp210 antibody was associated with a more severe cholestatic manifestation and a worse long-term prognosis. The anti-gp210 antibody could be added to further optimise the UK-PBC and GLOBE scoring systems.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 733-743 |
| Number of pages | 11 |
| Journal | Alimentary Pharmacology and Therapeutics |
| Volume | 45 |
| Issue number | 5 |
| DOIs | |
| State | Published - Mar 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
Cite this
The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis : the additional effect of anti-gp210. / Yang, F.; Yang, Y.; Wang, Q.; Wang, Z.; Miao, Q.; Xiao, X.; Wei, Y.; Bian, Z.; Sheng, L.; Chen, X.; Qiu, D.; Fang, J.; Tang, R.; Gershwin, M. Eric; Ma, X.
In: Alimentary Pharmacology and Therapeutics, Vol. 45, No. 5, 01.03.2017, p. 733-743.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis
T2 - the additional effect of anti-gp210
AU - Yang, F.
AU - Yang, Y.
AU - Wang, Q.
AU - Wang, Z.
AU - Miao, Q.
AU - Xiao, X.
AU - Wei, Y.
AU - Bian, Z.
AU - Sheng, L.
AU - Chen, X.
AU - Qiu, D.
AU - Fang, J.
AU - Tang, R.
AU - Gershwin, M. Eric
AU - Ma, X.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Background: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK-PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. Aim: To validate the UK-PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK-PBC and GLOBE scoring systems. Methods: We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti-gp210+ and 143 anti-gp210− patients. Results: The 5-year adverse outcome-free survivals of anti-gp210+ vs. anti-gp210− patients were 70% and 85%, respectively (P = 0.005). Cirrhosis (P = 0.001), albumin level ≤40 g/L (P = 0.011) and platelet count ≤153 × 109 (P < 0.001) had a superimposition effect on anti-gp210 antibody as a risk factor. Furthermore, long-term prognoses were evaluated using the UK-PBC and GLOBE scores. For UK-PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti-gp210+ patients (n = 110) and 0.888 for anti-gp210− patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti-gp210+ patients (n = 110) and 0.848 for anti-gp210− patients (n = 113). UK-PBC score >0.0578 (P < 0.001, HR: 32.736, 95% CI: 11.368–94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95% CI: 7.968–44.180) were associated with poorer outcomes in the whole cohort. Conclusions: The UK-PBC and GLOBE scoring systems were good 5-year prognostic predictors in Chinese patients with PBC, especially in anti-gp210+ patients. As a biomarker, anti-gp210 antibody was associated with a more severe cholestatic manifestation and a worse long-term prognosis. The anti-gp210 antibody could be added to further optimise the UK-PBC and GLOBE scoring systems.
AB - Background: Adequate risk stratification is critical for the management of the patients with primary biliary cholangitis (PBC). The UK-PBC and GLOBE scoring systems for prognosis of PBC have been proposed recently, but have not been validated in Asian population. Aim: To validate the UK-PBC and GLOBE scoring systems in Chinese patients for prognosis of PBC. To clarify the role of anti-gp210 as a biomarker, and to investigate whether anti-gp210 could affect the prognostic values of UK-PBC and GLOBE scoring systems. Methods: We retrospectively analysed 276 patients with PBC evaluated between September 2004 and May 2016, including 133 anti-gp210+ and 143 anti-gp210− patients. Results: The 5-year adverse outcome-free survivals of anti-gp210+ vs. anti-gp210− patients were 70% and 85%, respectively (P = 0.005). Cirrhosis (P = 0.001), albumin level ≤40 g/L (P = 0.011) and platelet count ≤153 × 109 (P < 0.001) had a superimposition effect on anti-gp210 antibody as a risk factor. Furthermore, long-term prognoses were evaluated using the UK-PBC and GLOBE scores. For UK-PBC scoring system, the area under receiver operating characteristic curve (AUROC) was 0.924 for all patients with PBC (n = 223), 0.940 for anti-gp210+ patients (n = 110) and 0.888 for anti-gp210− patients (n = 113). For GLOBE scoring system, the area under receiver operating characteristic curve was 0.901 for all patients with PBC (n = 223), 0.924 for anti-gp210+ patients (n = 110) and 0.848 for anti-gp210− patients (n = 113). UK-PBC score >0.0578 (P < 0.001, HR: 32.736, 95% CI: 11.368–94.267) and GLOBE score <0.850 (P < 0.001, HR: 18.763, 95% CI: 7.968–44.180) were associated with poorer outcomes in the whole cohort. Conclusions: The UK-PBC and GLOBE scoring systems were good 5-year prognostic predictors in Chinese patients with PBC, especially in anti-gp210+ patients. As a biomarker, anti-gp210 antibody was associated with a more severe cholestatic manifestation and a worse long-term prognosis. The anti-gp210 antibody could be added to further optimise the UK-PBC and GLOBE scoring systems.
UR - http://www.scopus.com/inward/record.url?scp=85009760514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009760514&partnerID=8YFLogxK
U2 - 10.1111/apt.13927
DO - 10.1111/apt.13927
M3 - Article
VL - 45
SP - 733
EP - 743
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 5
ER -